Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sym 023

Next Previous
X
Search
Drug Profile

Sym 023

Alternative Names: Anti-TIM-3; S 095018; S 95018; Sym-023

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Symphogen
  • Developer Servier; Symphogen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours
  • No development reported Lymphoma

Most Recent Events

  • 26 Jul 2024 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, In adults, Metastatic disease, Late-stage disease, Combination therapy) in Hong Kong, USA (IV) (NCT06162572)
  • 15 Jun 2024 Sym 023 is still in phase-I in Solid-tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV, Infusion), USA (IV, Infusion) and phase-I Solid-tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion), Canada (IV, Infusion) (Servier pipeline, June 2024)
  • 03 Jun 2024 Symphogen A/S completes a phase I trial in Solid tumors (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, France, Canada (IV) (NCT04641871)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top